Elkholy K, Akhtar H, Chakraborti A
Cureus. 2020; 12(8):e9831.
PMID: 32953340
PMC: 7495962.
DOI: 10.7759/cureus.9831.
Karlsson E, Molin L, Norlander B, Sjoqvist F
Br J Clin Pharmacol. 2012; 1(6):467-75.
PMID: 22454932
PMC: 1402529.
DOI: 10.1111/j.1365-2125.1974.tb01696.x.
Rothschild B
Clin Rheumatol. 2010; 29(9):999-1005.
PMID: 20544243
DOI: 10.1007/s10067-010-1513-4.
Siraki A, Deterding L, Bonini M, Jiang J, Ehrenshaft M, Tomer K
Chem Res Toxicol. 2008; 21(5):1143-53.
PMID: 18489081
PMC: 2766841.
DOI: 10.1021/tx700415b.
Podevin P, Biour M
Clin Rev Allergy Immunol. 1995; 13(3):223-44.
PMID: 8535929
DOI: 10.1007/BF02771763.
Effect of thiol compounds on human complement component C4.
Edmonds S, Gibb A, Sim E
Biochem J. 1993; 289 ( Pt 3):801-5.
PMID: 8435078
PMC: 1132247.
DOI: 10.1042/bj2890801.
Arylamine N-acetyltransferase activity in human cultured cell lines.
Coroneos E, Sim E
Biochem J. 1993; 294 ( Pt 2):481-6.
PMID: 8396914
PMC: 1134479.
DOI: 10.1042/bj2940481.
Adverse effects of direct-acting vasodilators.
Armario P, Hernandez del Rey R, Pardell H
Drug Saf. 1994; 11(2):80-5.
PMID: 7946001
DOI: 10.2165/00002018-199411020-00002.
Selecting appropriate antihypertensive drug dosages.
Johnston G
Drugs. 1994; 47(4):567-75.
PMID: 7516856
DOI: 10.2165/00003495-199447040-00001.
Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.
Harland S, Facchini V, Timbrell J
Br Med J. 1980; 281(6235):273-4.
PMID: 7427242
PMC: 1713780.
DOI: 10.1136/bmj.281.6235.273-a.
Hydrallazine-induced cutaneous vasculitis.
Bernstein R, Webster J
Br Med J. 1980; 280(6208):156-7.
PMID: 7357301
PMC: 1600356.
DOI: 10.1136/bmj.280.6208.156-a.
Hydralazine lung.
Bass B
Thorax. 1981; 36(9):695-6.
PMID: 7314046
PMC: 471705.
DOI: 10.1136/thx.36.9.695.
Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.
Facchini V, Timbrell J
Br J Clin Pharmacol. 1981; 11(4):345-51.
PMID: 7259927
PMC: 1401654.
DOI: 10.1111/j.1365-2125.1981.tb01131.x.
Acute low-dose hydralazine induced lupus syndrome (HILS).
Chisholm Jr J
J Natl Med Assoc. 1981; 73(3):278-80.
PMID: 7205989
PMC: 2609808.
A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients.
Silas J, Phillips F, Freestone S, Tucker G, Ramsay L
Eur J Clin Pharmacol. 1981; 19(2):113-8.
PMID: 7202470
DOI: 10.1007/BF00568397.
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.
Weinshilboum R, Sladek S
Am J Hum Genet. 1980; 32(5):651-62.
PMID: 7191632
PMC: 1686086.
Clinical pharmacokinetics of hydralazine.
Ludden T, McNay Jr J, Shepherd A, Lin M
Clin Pharmacokinet. 1982; 7(3):185-205.
PMID: 7047041
DOI: 10.2165/00003088-198207030-00001.
Adverse effects of antihypertensive drugs.
Husserl F, Messerli F
Drugs. 1981; 22(3):188-210.
PMID: 7021123
DOI: 10.2165/00003495-198122030-00002.
Acetylator phenotype and lupus erythematosus.
Uetrecht J, Woosley R
Clin Pharmacokinet. 1981; 6(2):118-34.
PMID: 7011656
DOI: 10.2165/00003088-198106020-00003.
Endralazine in patients with severe hypertension and renal insufficiency.
Higgs E, Harrison P, Banks R, Kingswood J, Mackenzie J
Postgrad Med J. 1982; 58(686):767-70.
PMID: 6984902
PMC: 2426600.
DOI: 10.1136/pgmj.58.686.767.
